POPULARITY
18 episodes with bausch lomb
6 episodes with bausch lomb
3 episodes with bausch lomb
3 episodes with bausch lomb
3 episodes with bausch lomb
2 episodes with bausch lomb
2 episodes with bausch lomb
2 episodes with bausch lomb
2 episodes with bausch lomb
South East Technological University (SETU) is proud to announce that Dr Laurence Fitzhenry, Principal Investigator of the Ocular Therapeutics Research Group (OTRG) in the PMBRC, and Research Group Manager Tess Ames have secured the prestigious INNOVISION COFUND, a €3.1 million collaborative research programme focused on addressing the global challenges of ocular disease and sight loss. This achievement marks a major milestone, with SETU becoming the first Technological University in Ireland to coordinate a Horizon Europe Marie Sklodowska-Curie COFUND programme. Vision impairment is a major and growing global health challenge impacting the quality of life, and overall health of billions of people worldwide. It also places a significant economic burden on individuals, healthcare systems, and societies at large. INNOVISION will tackle this problem across disciplines, departments, and around the world, enabling researchers to take holistic approaches to this problem. "This is a global health crisis that demands urgent, innovative solutions to preserve quality of life for millions. By putting those living with ocular disease at the forefront of research, INNOVISION gives us the opportunity to really address this crisis." Dr Fitzhenry stated. INNOVISION brings together a world-class network of partners, including the University of Iceland and Experimentica (Finland) to recruit highly qualified postdoctoral researchers to tackle the growing concern of ocular disease. Additional collaborators span the globe, notably McMaster University (Canada) and the University of Colorado Anschutz Medical Campus (USA), and patient advocacy organisations Fighting Blindness (Ireland) and the Dry Eye Foundation (USA). Additional network partners include University College Dublin, Queens University Belfast, University of Birmingham, Instituto Superior Tecnico, Universidade de Santiago de Compostela, Universidad Complutense de Madrid, Loyola University Chicago, Rowan University, and industry leaders including Bausch+Lomb, SiriusXT, OcuDel, and OcuMedic. Professor Veronica Campbell, SETU President commented, "We are delighted to launch INNOVISION and work with outstanding global partners to tackle this critical challenge. This initiative not only provides a unique opportunity for researchers and industry alike to make a real difference in people's lives, but it demonstrates that SETU and Ireland's South East are a driver of innovative, impactful, and creative research. We are especially pleased to see such strong engagement from industry partners, whose involvement will help ensure that research outcomes translate into real-world solutions for people living with vision impairment." Over the course of the programme, INNOVISION will recruit 12 experienced postdoctoral researchers to work across this global network. These researchers will embark on cutting-edge projects exploring a wide range of topics, including drug delivery, drug discovery, and novel therapeutic approaches to combat vision impairment and blindness. "Industry involvement is a vital part of INNOVISION's mission. We want to continue to grow the network over the next five years, expanding the potential for impact and real-world benefits", says Programme Manager Tess Ames. Companies or other research organisations interested in contributing to or collaborating with the programme are encouraged to reach out to Tess at tess.ames@setu.ie for more information on how to get involved. This project has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Sklodowska-Curie COFUND scheme (Grant Agreement No. 101217199). More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upc...
In this episode, we are joined by Yang Yang, President, Vision Care at Bausch + Lomb, who shares her experiences throughout her 11+ years in the eye care industry, wisdom she learned throughout her career, and advice for others to grow their careers and leadership opportunities. Yang Yang also provides insights on mentorship, how travel can enrich your role, and her hopes for the future of eye care.About the guest:Yang Yang was appointed President, Vision Care, in June 2023, after previously serving as Senior Vice President, Global Vision Care, since November 2021. Ms. Yang joined Bausch + Lomb in February 2014, serving in positions of increasing responsibility. Previously, she served as Vice President, International Vision Care, from 2017 to 2021, and as Business Unit Director, Vision Care, China and Japan.Before joining Bausch + Lomb, Ms. Yang led marketing and sales teams for Johnson & Johnson, L'Oréal and Proctor & Gamble. She holds an MBA from the Stephen M. Ross School of Business at the University of Michigan and a bachelor's degree in English Literature from Peking University.Like this episode? Please subscribe and share!iTunes | Spotify | Overcast | iHeartRadio | AmazonConnect with the OWA:Website | LinkedIn | Instagram | Facebook
Send us a textAbout:Alex Kotelsky is a medical device engineer at Bausch + Lomb where he leads innovative optical projects in the research and development of advanced contact lens designs.With a robust background in both theoretical and applied sciences, Alex has a Ph.D. and has postdoctoral training in biomechanics and mechanobiology of articular cartilage and chondrocytes. His research has produced multiple peer-reviewed publications that shed light on the mechanical interactions within biological systems. By integrating biology, mechanics and optics, Alex brings aninterdisciplinary approach that advances both the performance and comfort of contact lenses, benefiting eye care professionals and patients alike.In addition to his research, Alex is deeply committed to education, fostering the next generation of engineers and scientists. His dedication to teaching has earned him multiple accolades, including the prestigious Edward Peck Curtis Award for Excellence in Teaching and recognition as a Top 3 Finalist for Tutor Doctor's Tutor of the Year 2019 award.James DiBella is a Senior Principal Scientist and head of Polymer Chemistry at Bausch + Lomb, where he leads a team focused on creating innovative materials and solutions for the contact lens and ophthalmic industries. Since joining Bausch + Lomb in 2015, James has been instrumental in product development for the company's vision care business. He notably co-invented Bausch + Lomb's latest contact lens technology - Bausch + Lomb INFUSE ® .He holds a bachelor's degree in Organic Chemistry from Clemson University as well as a master's degree in Organic Chemistry from the Florida Institute of Technology. He is also in the process of obtaining a master's degree in business administration from Manning School of Business at the University of Massachusetts to merge his scientific expertise with strategic business acumen.
South East Technological University (SETU), in collaboration with the Engineering the South East Cluster (ESE) and its automation sub-group, is proud to announce the launch of an innovative multi-company automation scholarship designed to retain top engineering talent within the region. A recent Higher Education Authority (HEA) report revealed that 62% of engineering students from the southeast region leave to study elsewhere, with a significant impact on the local workforce. In response to this, SETU's Autom8 scholarship initiative aims to attract and support students pursuing automation and robotics engineering careers, while addressing the region's growing demand for skilled professionals in industry. Speaking at the launch of the scholarship, Stephen Rooney, Cluster Manager, Engineering the South East, SETU, said, "The Autom8 scholarship is set to enhance local career opportunities, reduce brain drain, and strengthen industry-academic collaboration. It aligns with SETU's mission to support regional economic growth by fostering a pipeline of skilled graduates who can drive technological innovation in the southeast." The Autom8 scholarship brings together a group of leading manufacturing and automation companies to offer students financial support, industry experience, and professional mentorship throughout their undergraduate studies at SETU. Companies partnering with SETU on this initiative include MSD Ireland, Integer, Teva, Sanofi, and Bausch + Lomb. Edmond Connolly, Manager, South East Regional Skills Forum, said "SETU and Engineering the South East encourage interested second-level students to apply and seize this opportunity to advance their careers in automation engineering within a thriving local industry." The scholarship is open to students enrolling on SETU's Bachelor of Engineering (B.Eng.) in Automation Engineering (Waterford campus) and the Bachelor of Robotics and Automated Systems (Carlow campus) Each participating company will provide a €2,000 annual contribution towards a student's educational expenses, along with access to paid summer work, a third-year industrial placement, and a dedicated industry mentor. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.
In this episode of The Rob & Jai Show, Dr. Rob Rothman and Dr. Jai Parekh host a captivating conversation with Andrew Stewart and Anthony Wallace—two leaders who are among the most experienced and admired executives in ophthalmology. Andrew Stewart, with over 25 years of pharmaceutical leadership across Bausch + Lomb, AbbVie, and Allergan, shares how his global business acumen shapes innovation in eye care. Anthony Wallace, a 26-year healthcare veteran with leadership roles at Novartis, Merck, and GlaxoSmithKline, reflects on leading Bausch + Lomb's U.S. Surgical business and his passion for patient-centered solutions. Both leaders bring a wealth of knowledge, relatable stories, and a shared commitment to advancing ophthalmic care.In this episode, you'll learn:
Doree and Elise share their trusted local and national news sources and hear from listeners about the pride of free mugging, the Apple Health app reminder hack, and the Sam's Club Chick-Fil-A dupe.This episode contains a sponsored segment by Bausch + Lomb. Visit Xiidra.com to learn more.To leave a voicemail or text for a future episode, reach Doree & Elise at 781-591-0390. You can also email the podcast at forever35podcast@gmail.com.Visit forever35podcast.com for links to everything they mention on the show or visit shopmyshelf.us/forever35.Follow the podcast on Instagram (@Forever35Podcast) and sign up for the newsletter at forever35podcast.com/newsletter. Hosted on Acast. See acast.com/privacy for more information.
Dor and Elise catch up before hearing from listeners with advice for last week's listener looking for the next step in their career, another all-in-one Ninja product you need to know about, who's free bowling what and where, and a call out for some Sam's Club recs!This episode contains a sponsored segment by Bausch + Lomb. Visit KnowYourDryEye.com for more information.To leave a voicemail or text for a future episode, reach Doree & Elise at 781-591-0390. You can also email the podcast at forever35podcast@gmail.com.Visit forever35podcast.com for links to everything they mention on the show or visit shopmyshelf.us/forever35.Follow the podcast on Instagram (@Forever35Podcast) and sign up for the newsletter at forever35podcast.com/newsletter. Hosted on Acast. See acast.com/privacy for more information.
Doree and Elise discuss how to be a supportive sister as a new mom, the different ways being proud of yourself and feeling fulfilled can look as you age, and the staggering savings that pet insurance brought one listener. This episode contains a sponsored segment by Bausch + Lomb. Visit miebo.com to learn more.To leave a voicemail or text for a future episode, reach Doree & Elise at 781-591-0390. You can also email the podcast at forever35podcast@gmail.com.Visit forever35podcast.com for links to everything they mention on the show or visit shopmyshelf.us/forever35.Follow the podcast on Instagram (@Forever35Podcast) and sign up for the newsletter at forever35podcast.com/newsletter. Hosted on Acast. See acast.com/privacy for more information.
Em parceria com a Bausch + Lomb, essa edição traz as doutoras Maria Auxiliadora Frazão e Elisabeth Guimarães em um bate papo leve e esclarecedor sobre o uso de lentes de contato. Assista, compartilhe e deixe seu comentário!
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28 Bausch + Lomb acquires Elios Vision 2:07 ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00 Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31 Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.
South East Technological University (SETU) proudly hosted the highly anticipated launch of TU RISE (TU Research and Innovation Supporting Enterprise) on Wednesday, 20 November, at SETU's Cork Road Campus. The event brought together industry leaders, academics, and policymakers to celebrate the transformative impact of TU RISE and its role in driving regional development. SETU President Professor Veronica Campbell's welcoming address highlighted the University's commitment to fostering innovation and collaboration through TU RISE. Prof. Marie Claire Van Hout, SETU's Vice President for Research, Innovation and Impact, followed with a strategic overview of the initiative, underlining its importance in enhancing SETU's engagement with regional enterprises. Prof. Campbell said, "The launch of TU RISE today represents not just a new initiative but a bold step forward in our collective journey toward excellence, opportunity, and impact. "The launch of TU RISE is a defining moment for SETU, but it is also an invitation: an invitation to all of us to step forward and be part of something greater. As we continue to build and grow this initiative, we must remember that it is only through collaboration, curiosity, and bold thinking that we will achieve the transformative impact we seek." Dr Geraldine Canny provided attendees with insights into TU RISE offerings, outlining the opportunities it presents for businesses and researchers. A highlight of the event was a round-table discussion on regional development and the critical role research plays in driving economic growth. Facilitated by Prof. Felicity Kelliher, the discussion featured leading experts, including Prof. Dominique Foray from EPFL, Dr James O'Sullivan, Head of Innovation and Commercialisation at SETU, and Louise Grubb, entrepreneur and director at Trivium Vet. Attendees also benefitted from thought-provoking presentations, including: • Dr Patrick Lynch's introduction to the TU RISE Digital Masterclass. • Ed Murphy of Greentech HQ, who shared actionable insights on adopting sustainability in regional companies. • Dr Laurence Fitzhenry and the OTRG team, who detailed their successful collaboration with Bausch + Lomb. • Michael Flynn of FLI Global, who spoke about his experience working with SETU on collaborative projects. The event was attended by a wide range of regional companies, SETU academics and staff, as well as representatives from regional development agencies and the Southern Regional Assembly. TU RISE is co-financed by the Government of Ireland and the European Union through the ERDF Southern, Eastern & Midland Regional Programme 2021-27.
Presbyopia, typically beginning in the late 30s, can hinder athletes who rely on quick, precise focus shifts. For shooters, this condition impacts contrast sensitivity, glare tolerance, and near-vision clarity. The Bausch + Lomb family of lenses—INFUSE®, ULTRA®, and Biotrue® ONEday—offers effective solutions, helping presbyopic shooters maintain peak visual performance.
On this Live Greatly podcast episode, Kristel Bauer sits down with Willie Pietersen, author of Leadership—The Inside Story: Time-Tested Prescriptions for Those Who Seek To Lead. Willie shares stories, experiences and the secret sauce of leadership learned from his time being CEO of multibillion-dollar businesses, a professor at Columbia University's Graduate School of Business, and a consultant to some of the world's biggest and best-known organizations. Tune in now! Key Takeaways From This Episode How leadership is all about people Some big lessons Willie learned amid his leadership journey How to get better at receving feedback and why it is important Stories about what makes a great leader About Willie Pietersen: Willie Pietersen was raised in South Africa, and received a Rhodes Scholarship to Oxford University. After practicing law, he embarked on an international business career. Over a period of twenty years he served as the CEO of multibillion-dollar businesses such as Lever Foods, Seagram USA, Tropicana and Sterling Winthrop's Consumer Health Group. In 1998, Willie was named Professor of the Practice of Management at the Columbia University Graduate School of Business. He specializes in strategy and the leadership of change, and his methods and ideas, especially Strategic Learning, are widely applied within Columbia's executive education programs, and also in numerous corporations. He has served as a teacher and advisor to many global companies, including Aviva, Bausch & Lomb, Boeing, Chubb Corp., Deloitte, DePuy, Electrolux, Ericsson, ExxonMobil, Henry Schein, Inc., Federal Home Loan Bank of Atlanta, Novartis, Salt River Project, SAP, UGI, United Nations Federal Credit Union and also the Girl Scouts of the USA. Willie is the author of three books and numerous articles. His latest book is Leadership—The Inside Story: Time-Tested Prescriptions for Those Who Seek to Lead. Connect with Willie: Website: https://williepietersen.com/ LinkedIn: https://www.linkedin.com/in/willie-pietersen-286b149/ Get Willie's Book: https://williepietersen.com/books/leadership-the-inside-story-time-tested-prescriptions-for-those-who-seek-to-lead/ About the Host of the Live Greatly podcast, Kristel Bauer: Kristel Bauer is a corporate wellness expert, popular keynote and TEDx speaker, and the host of top-rated self-improvement podcast “Live Greatly”. Kristel is an Integrative Medicine Fellow & Physician Assistant with clinical experience in Integrative Psychiatry, giving her a unique perspective into optimizing mental well-being and attaining a mindset for more happiness and success in the workplace and beyond. Kristel decided to leave clinical practice in 2019 when she founded her wellness platform “Live Greatly” to share her message around well-being and success on a larger scale. With a mission to support companies and individuals on their journeys for more happiness, success, and well-being, Kristel taps into her unique background in healthcare, business, and media, to provide invaluable insights into high power habits, leadership development, mental well-being, peak performance, resilience, sales, success, wellness at work, and a modern approach to work/life balance. Kristel is the author of Work-Life Tango: Finding Happiness, Harmony and Peak Performance Wherever You Work (John Murray Business November 19, 2024). Kristel is a contributing writer for Entrepreneur and she is an influencer in the business and wellness space having been recognized as a Top 10 Social Media Influencer of 2021 in Forbes. A popular speaker on a variety of topics, Kristel has presented to groups at APMP, Bank of America, Commercial Metals Company, General Mills, Northwestern University, Mazda, Santander Bank and many more. She has been featured in Forbes, Forest & Bluff Magazine, Authority Magazine & Podcast Magazine, has contributed to CEOWORLD Magazine & Real Leaders Magazine, and has appeared on ABC 7 Chicago, WGN Daytime Chicago, Fox 4's WDAF-TV's Great Day KC and Ticker News. Kristel lives in the Chicago area with her husband and their 2 children. She can be booked for speaking engagements worldwide. To Book Kristel as a speaker for your next event, click here. Website: www.livegreatly.co Follow Kristel Bauer on: Instagram: @livegreatly_co LinkedIn: Kristel Bauer Twitter: @livegreatly_co Facebook: @livegreatly.co Youtube: Live Greatly, Kristel Bauer To Watch Kristel Bauer's TEDx talk of Redefining Work/Life Balance in a COVID-19 World click here. Click HERE to check out Kristel's corporate wellness and leadership blog Click HERE to check out Kristel's Travel and Wellness Blog Disclaimer: The contents of this podcast are intended for informational and educational purposes only. Always seek the guidance of your physician for any recommendations specific to you or for any questions regarding your specific health, your sleep patterns changes to diet and exercise, or any medical conditions. Always consult your physician before starting any supplements or new lifestyle programs. All information, views and statements shared on the Live Greatly podcast are purely the opinions of the authors, and are not medical advice or treatment recommendations. They have not been evaluated by the food and drug administration. Opinions of guests are their own and Kristel Bauer & this podcast does not endorse or accept responsibility for statements made by guests. Neither Kristel Bauer nor this podcast takes responsibility for possible health consequences of a person or persons following the information in this educational content. Always consult your physician for recommendations specific to you.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Senseonics has received FDA clearance for a one-year continuous glucose monitoring system. The company's commercial partner, Ascensia, is in talks with insulin pump manufacturers to create an automated insulin delivery system. Zimmer is pulling its hip implant off the market due to fracture risk, Bausch + Lomb is considering a sale, and Masimo investor claims a proxy war win as CEO Joe Kiani fails to retain a board seat. The wearables market is expected to see significant growth, with adhesives playing a vital role in development. Other noteworthy stories include DermaSensor's skin cancer detection device, a Senate committee holding Steward CEO in contempt, and Medtronic detailing a study of adaptive neurostimulation in Parkinson's disease.Brisk Iced Tea brought back its classic claymation ad campaign featuring Doja Cat to target Gen Z. E.l.f. launched a skincare campaign with "Sinfluencer" Megan Stalter. Pizza Hut put resumes on boxes to help job seekers stand out. Frito-Lay used burner phones in a campaign targeting Gen Z for Flamin' Hot Cheetos. Chipotle planned a digital scavenger hunt to give out $1 million in free quesadillas. Customers' trust in AI is low, impacting purchasing decisions.Cigna is scaling back its Medicare Advantage footprint in 8 states next year, affecting roughly 5,400 members, mostly in Florida. Johnson & Johnson is facing sanctions over a plan to rebate 340B drugs, while Express Scripts is suing the FTC over a report criticizing pharmacy benefit managers. The US is behind other wealthy nations in healthcare despite spending the most, with a Commonwealth Fund analysis ranking the US last in access to care and health outcomes.Cigna is reducing its Medicare Advantage footprint in 8 states, affecting around 5,400 members, mainly in Florida. CarePoint Health may lay off 2,600 employees due to financial struggles. The House committee passed a bill to extend telehealth flexibilities in Medicare for another two years. Steward Health Care auctioned assets, with Christus Health set to purchase a Texas-based medical center for $4.5 million.MilliporeSigma is partnering with an experienced viral vector CDMO to offer solutions for the production of cell and gene therapies. They invite attendees of the Mesa conference in Phoenix to visit their booth or schedule a meeting to learn about their viral vector development and manufacturing capabilities.The Senate has voted to hold Steward CEO in contempt for defying a congressional subpoena. The US healthcare system lags behind other wealthy nations in performance despite spending the most. Oak Street Health pays $60 million to settle allegations of a kickback scheme, and J&J faces sanctions over a plan to rebate 340B drugs.Medtech news from September 19, 2024, includes updates on various companies and developments in the industry. Masimo's proxy fight is coming to an end, with a shareholder vote looming. Axonics wins a patent dispute against Medtronic, while Boston Scientific's proposal to buy Axonics is still under review.A startup from George Church's lab has raised $75 million to develop 'supercell' medicines, claiming it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods. Roche's Xofluza has shown promising results in reducing flu transmission in a phase 3 study, marking the first time an antiviral drug has achieved this in a global trial.The text discusses the latest advances in oncology research presented at the ESMO conference, focusing on the challenges faced by the pharmaceutical industry in expanding patient access and improving cancer research outcomes.The text promotes a webinar by QT Group on September 26th focusing on continuous compliance for medical software, specifically addressing how to maintain software quality and compliance with medical standa
Dr. Jill Saxon shares with Dr. Joseph Allen how her officer training in the Navy helped her become the leader she is today and she shares the story of a specific soldier that helped inspire her to think big and give back. She then transitioned to private practice in her hometown in New Jersey, where she had the opportunity to work with Bausch + Lomb as a consultant. Eventually, B+L approached her with the opportunity to join full time. She discussed her 10 years in industry and its global impact on optometry and patient care, starting with her early input on developing the INFUSE contact lens. Listen in and get inspired to move optometry forward! Eye Give a Damn hosted by Dr. Joseph Allen is produced by FluoreSCENE Media.For more information on Dr. Joseph Allen visit https://doctoreyehealth.com/Visit https://odcommunity.com/ to learn more about FluoreSCENE Media.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Delays in clinical trials can cost up to $8 million per day, making it crucial to understand and address the main factors causing these setbacks. Strategies to keep clinical trials on schedule include identifying common issues that slow down studies, addressing challenges effectively to minimize risks, and understanding potential financial losses to avoid them. By taking control of clinical trial timelines, researchers can prevent costly delays and ensure successful completion of studies.Senseonics has received FDA clearance for a continuous glucose monitoring (CGM) device that can be worn for up to 365 days. Boston Scientific has closed its acquisition of Silk Road Medical, while Smiths Medical has recalled airway tubes due to a defect that has caused more than 10 injuries. Medtech firms have cut over 14,000 jobs in the past 18 months. Exact Sciences has announced that data supports its colon cancer blood test, which could compete with Guardant Health's similar test. Bausch + Lomb is considering a sale, with private equity firms being potential buyers. The wearables market is expected to grow by 13% annually between 2024 and 2030.Merck's ADC data shows promising results in a lung cancer trial, while Ascendis' trial data puts pressure on Biomarin. Nura Bio secures $68 million in funding for neuroprotective brain drugs. The Biosecure bill could lead to drugmakers pivoting towards China. ESMO24 highlights include a cancer cachexia drug and the impact of immunotherapy on survival rates. Drug development leaders are turning to AI to drive efficiency.Cigna is suing the FTC over a report on pharmacy benefit managers, while employer health costs are expected to rise by 5.8% per employee in 2025. Johns Hopkins has appointed a new cybersecurity chief, and healthcare worker strikes are being tracked, such as nurses at Brigham and Women's Faulkner Hospital planning a strike. Employers are making cost-cutting changes to health plans, and the impact of mentorship in healthcare is highlighted.Pizza Hut is using its pizza boxes to help job seekers get noticed by putting resumes on them. Frito-Lay's campaign targeted at Gen Zers encourages fans to cheat on Flamin' Hot Cheetos with other brands. The US ad spending rebound is proving to be robust beyond cyclical events, such as the Olympics. However, customers don't trust AI, which could be hurting businesses as it decreases purchasing intention.The pharmaceutical industry is facing challenges in expanding patient access and improving cancer research outcomes. Compassionate use, also known as expanded access, provides unapproved drugs to terminally ill patients as a last resort. Radiopharmaceuticals have seen a resurgence in activity and interest from big pharma for treating cancer. Ratio Therapeutics advocates for compassionate use due to the low-risk, high-reward nature of radiopharmaceuticals. Despite challenges like patient safety and ongoing clinical trials, radiopharmaceuticals are gaining momentum in the industry. Big pharma companies are embracing this trend, with smaller players also making waves in the market. The industry is exploring strategies for better site selection in clinical trials and enhancing efficiency during gene therapy development.
Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Commerzbank-Drama geht in nächste Runde. CEO von Bausch + Lomb ist in seinem Element. Apple hat schwache Vorverkäufe, Intel hat starken Auftrag, Bajaj hat gigantischen Börsengang, Mercedes hat hohen E-Auto-Absatz in Indien. Pickleball ist und bleibt eine Trendsportart. Der Athletic Country Club “Life Time Group” (WKN: A3C4Y1) ist und bleibt ein Profiteur dieser Trendsportart. Ist Action das nächste Aldi? Der ehemalige Aldi-Süd-Chef scheint das zu denken. Die Zahlen geben ihm recht und 3i (WKN: A0MU9Q) hat mit Action ohnehin den Deal des Jahrhunderts gemacht. Diesen Podcast vom 17.09.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.
In this episode, we're joined by the legendary Brent Saunders. Brent Saunders is a world-renowned Fortune 500 CEO who has completed more than $300 billion in mergers & acquisitions throughout his career. He is the CEO of Bausch + Lomb, Chairman of Roam, and former CEO of Allergan, which he sold to AbbVie for $83 billion. He is a pioneer in the health & beauty industry and is directly responsible for building some of the biggest consumer brands, including Botox, Claritin, and Coppertone.This is not just a conversation; it's a masterclass in leadership, strategy, and the skills required to steer a global pharmaceutical giant.
On this episode, I was joined by Maysaa Attar, Senior Vice President of R&D at Bausch + Lomb. On this episode, Maysaa discusses: 00:00 Welcome to Episode 150! 03:00 Challenges and Innovations in Ocular Drug Delivery 09:30 Understanding Intravitreal Injections 13:26 Regulatory Considerations for Ocular Products 20:48 Innovations in Glaucoma Treatment 29:18 The Personal Impact of Vision Loss 35:40 Book Recommendations and Final Thoughts Maysaa Attar is the Senior Vice President of R&D at Bausch & Lomb, leading global pharmaceutical and consumer product research and development. She has held prominent leadership positions at Abbvie and Allergan and holds a PhD in Pharmaceutical Sciences from the University of Southern California (USC), where she also serves as a professor.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care. • Welcome to the Eyeluminaries podcast :05 • Review of episode 25 :46 • Bausch + Lomb acquires Trukera Medical 1:32 • CMS proposes cutting physician payments for fifth straight year 4:09 • FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 • FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 • Intro of Cathleen McCabe, MD 13:07 • American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 • In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 • Besides the two of us, who do you admire in ophthalmology? 23:37 • Tell us about your work, what you do and how you do it. 27:21 • Preview of episode 27 33:30 • Thanks 34:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.
Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Luxus und China sind schwierige Märkte. Das zeigen Burberry und Swatch. Indien ist ein attraktiver Markt und Geld gibt's viel. Das zeigen BlackRock und Apple. Außerdem ist BayWa in der Krise, Alphabet zahlt Milliarden für 4 Jahre Arbeit und Trump-Aktie steigt. Bausch + Lomb (WKN: A3DLMS) hat die Ray-Ban-Sonnenbrillen erfunden, weiche Kontaktlinsen auf den Markt gebracht und einen der krassesten Wirtschaftsskandale ever erlebt. Mineral Resources (WKN: A0J36A) ist das Amazon der Bergbauwelt. Diesen Podcast vom 16.07.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.
A quality culture seem to be a nice to have. But after listening this podcast episode with Lesley Worthington, you will see that it is worth to build one. We will review the description of a quality culture and how to build it. But also if this is required by a regulation and how you can align it with your compliance duties. Check this and share it with your team. Who is Lesley Worthington? Lesley works with individuals and teams to fine-tune their Quality conversations, initiatives, and internal communications to create a better understanding of the role and concepts of quality assurance throughout their organization. Through her leadership and executive coaching, she supports professionals as they work on improving their relationships and effectiveness in their roles allowing them to achieve their fullest potential, professionally, and empowering them to move their organizations toward a robust Quality Culture. She runs a community, The Quality Network, which supports Quality professionals as they work on the skills that allow them to build a Quality Culture. The Quality Network is a place for learning, coaching, support, and networking and includes webinars, resources, a member platform, courses, and office hours. She combines 20 years of quality and regulatory experience in medical devices, in Canada, with thousands of hours of teaching and coaching to provide her clients with the skills, techniques, insights, and mindset that raise their confidence, take their communication skills to the next level, and allow them to have a positive impact in their organizations. She's got a Psychology Degree, a Law Degree, English as a Second Language Teaching Qualifications, and is a Certified Executive Coach. Who is Monir El Azzouzi? Monir El Azzouzi, a distinguished expert in the medical device sector, holds a Biomedical Engineering degree from ISIFC in France. With extensive experience at top-tier companies such as Bausch+Lomb, Aesculap, and Johnson & Johnson, Monir has a deep understanding of the industry's challenges and opportunities. His commitment to enhancing industry standards and support led him to establish Easy Medical Device. Easy Medical Device is an innovative company dedicated to enriching the medical device community through educational outreach such as podcasting, blogging, and video creation. The company also offers specialized training programs, notably the Green Belt Certificate for EU MDR, to elevate professional skills within the industry. Beyond education, Easy Medical Device provides comprehensive consulting services, helping manufacturers navigate the complexities of CE Marking, FDA registration, clinical evaluation reports, internal audits, design and development, supplier reviews, eQMS implementation, and due diligence. Our expertise extends to acting as authorized representatives and importers in Europe, Switzerland, and the UK, facilitating smoother market entry for our clients. Monir's vision for Easy Medical Device is to establish it as the definitive one-stop shop for all services related to medical device manufacturers. We are committed to assisting you in introducing and advancing your projects with efficiency and compliance. Do not hesitate to contact Monir El Azzouzi at Easy Medical Device to explore how we can support your medical device initiatives. Links LinkedIn: https://www.linkedin.com/in/lesleyworthington/ Website: https://lesleyworthington.com/ Email: lesley@lesleyworthington.com Social Media to follow Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi Twitter: https://twitter.com/elazzouzim Pinterest: https://www.pinterest.com/easymedicaldevice Instagram: https://www.instagram.com/easymedicaldevice
Don't miss the latest episode of the OIS Retina Podcast, where we sit down with optometrist and ophthalmology researcher Brian Levy for an illuminating discussion on the future of eye care. In this episode, Brian takes us on a journey through his career, from his early days in vet school to his groundbreaking work at Presbyterian Medical Center, Aerie Pharmaceuticals, Bausch + Lomb and currently at InflammX Therapeutics. Here are some key talking points from the episode:
Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 · If you could change anything in the ophthalmic industry, what would it be? 42:53 · How excited are you about robotics? 44:06 · Tell us about your promotion 44:52 · How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18 Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.
Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, kick off 2024 with a conversation about several new and anticipated products for treating ocular surface disease, including cyclosporine ophthalmic solution 0.1% (Vevye, Harrow), perfluorohexyloctane ophthalmic solution (Meibo, Bausch + Lomb), and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals). They also share some practice pearls and professional goals for the year ahead.
Several major pharmaceutical companies have issued a recall of certain eye drops due to potential contamination. This recall affects dozens of popular eye drop brands, including Visine, Clear Eyes, and Bausch + Lomb. You can find the complete list here. The recall is due to the discovery of a type of bacteria known as Burkholderia…
David Ware is the Vice President, Tax at Bausch + Lomb. In this episode of On Tax, he and Cravath partner and host Len Teti talk about how his early interest in accounting led him to become a tax associate at Cravath. They also discuss his path to his current position as the head of tax at a publicly traded company, a role in which tax accounting is critical. Hosted on Acast. See acast.com/privacy for more information.
Keith Lewis is a seasoned veteran in marketing, sales, and the medical industry. He is currently the Senior Advisor at ChampionOne Group and Principal at Lewis Ventures, LLC. Across his 40+ year career, he has worked at GN ReSound, Bausch & Lomb, and GN Great Nordic. His passion is for patients and shareholders alike, focusing on helping those affected by hearing loss. In this episode… While hearing aid technology is primarily a medical issue, it inevitably becomes a business issue under the Western medical system. Companies, brands, insurance, and clinics all have a vested interest in the financial aspects of the industry. This has its own effect on how hearing technology grows and adapts. The industry is always experiencing new research and innovations. The average consumer is being provided more education, options, and treatment than ever before — this is what you need to know from an active insider. In this episode of the ListenUp! Podcast, Dr. Mark Syms talks with Keith Lewis, the Principal at Lewis Ventures, LLC, to talk about the business and evolution of the hearing tech industry. They break down the financial realities of hearing aids, how Bluetooth is being utilized, and how the retail price is changing. They also touch on the current and potential future market trends.
Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO, discuss factors to consider when bringing perfluorohexyloctane ophthalmic solution (Miebo, Bausch + Lomb) and lotilaner ophthalmic solution 0.25% (Xdemvy, Tarsus Pharmaceuticals) into your clinical practice.
“You can see and feel a buzz within the company right now,” said Andrew Stewart, President, Global Pharmaceuticals and International Consumer, at Bausch + Lomb.Bausch + Lomb's current momentum stems not only from new leadership, but also from recent collaborations, partnerships, and acquisitions.Stewart and Yehia Hashad, MD, Executive Vice President of Research & Development and Chief Medical Officer, join host Paul Karpecki, OD, to discuss these activities. Miebo, the first-in-class dry eye asset for the treatment of evaporative dry eye, tops the list.Looking ahead, Stewart and Dr. Hashad said the company is lasering its focus to tackle more unmet medical needs in eye care. The company intends to build on its legacy of innovation in drug delivery, in MOAs, and in developing new molecular entities.What's next for the most recognized name in eye care?Topics discussed include:Why Stewart shifted into commercial from R&D, and why Dr. Hashad moved from clinical practice to R&D.How Bausch + Lomb leadership is looking at the future for a company with a 170-year legacy.Bausch + Lomb's holistic approach to dry eye disease and treatment.The company's thinking behind acquiring the rights from Novaliq to pursue development of what is now Miebo.The importance of addressing unmet needs with respect to the Bausch pipeline.What excites Dr. Hashad and Stewart about the company right now.Where they would like to see Bausch + Lomb in the next three to five years, including for Miebo, for ocular surface disease treatments, and for eye care.ResourcesMiebo https://www.miebo.comAndrew Stewart https://www.bausch.com/about-bausch-lomb/leadership-teamYehia Hashad, MD https://www.bausch.com/about-bausch-lomb/leadership-teamPaul Karpecki, OD https://ois.net/paul-karpecki-od
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more. Welcome to the Eyeluminaries podcast :01 Review of episode 17, live from Octane OTF :41 Bausch + Lomb makes a number of big moves under the new Brent Saunders regime 1:40 Mark Baum and Harrow Health have also been making a number of acquisitions 3:59 FDA approves Xdemvy for Demodex blepharitis treatment 5:45 Former CEO of Johnson & Johnson Alex Gorsky elected lead director of Neurotech's board 7:47 John begins new clinical committee for ASCRS, digital 9:32 Julia Haller, MD introduction 11:30 ReST Committee update on intraocular inflammation reported in patients who received Syfovre at the American Society of Retina Specialists annual meeting 13:44 The FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma 14:16 Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration 14:36 How has the latest retina news affected patients and physicians? 14:53 The development of biosimilars 19:50 Discussion on pricing of products 21:57 The evolution and future of residency programs 23:34 Fun with retina drug names 27:15 Preview of episode 19 at OSN New York 29:46 Feedback, questions and guest suggestions at eyeluminaries@healio.com 30:15 Thanks for listening 30:27 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.
A life of Service: Dr. Jill Saxon talks with new OWA Talks co-hosts, Tatiana and Carissa, about her journey in the industry. Through a career in optometry and her service in the US Navy, Dr. Saxon has made a meaningful impact on the world. Listen to this inspirational episode to hear Dr. Saxon's story, drawing from family members in Optometry and private practice to her role as Executive Director, Professional Strategy at Bausch + Lomb.
ABOUT Susan Magsamen and Ivy Ross:Susan's LinkedIn profile: https://www.linkedin.com/in/susan-magsamen-6345918/Ivy's Profile: linkedin.com/in/rossivyWebsites:Website: www.yourbrainonart.comInstagram: https://www.instagram.com/yourbrainonartbook/LinkedIn: https://www.linkedin.com/company/your-brain-on-art/Facebook: https://www.facebook.com/profile.php?id=100089357061217&mibextid=LQQJ4d BIO - Susan Magsamen:Susan Magsamen is the founder and executive director of the International Arts + Mind Lab (IAM Lab), Center for Applied Neuroaesthetics, a pioneering initiative from the Pedersen Brain Science Institute at Johns Hopkins University School of Medicine. Her body of work lies at the intersection of brain sciences and the arts—and how our unique response to aesthetic experiences can amplify human potential. Magsamen is the author of the Impact Thinking model, an evidence-based research approach to accelerate how we use the arts to solve problems in health, well-being, and learning. In addition to her role at IAM Lab, she is an assistant professor of neurology at Johns Hopkins and serves as co-director of the NeuroArts Blueprint project in partnership with the Aspen Institute.Prior to founding IAM Lab, Magsamen worked in both the private and public sector, developing social impact programs and products addressing all stages of life—from early childhood to the senior years. Magsamen created Curiosityville, an online personalized learning world, acquired by Houghton Mifflin Harcourt in 2014 and Curiosity Kits, a hands-on multi-sensory company, acquired by Torstar in 1995.An award-winning author, Magsamen has published eight books including The Classic Treasury of Childhood Wonder, The 10 Best of Everything Families, and Family Stories.Magsamen is a Fellow at the Royal Society of the Arts and a strategic advisor to several innovative organizations and initiatives, including the Academy of Neuroscience for Architecture, the American Psychological Association, the National Association for the Education of Young Children, Brain Futures, Learning Landscapes, and Creating Healthy Communities: Arts + Public Health in America. BIO - Ivy Ross:Ivy Ross is the Vice President of Design for the Hardware organization at Google. Over the past six years, she and her team have launched 50+ products winning over 240 global design awards. This collection of hardware established a new Google design aesthetic that is tactile, colorful, and bold. A winner of a National Endowment for the Arts grant, Ivy's innovative metal work in jewelry is in the permanent collections of 12 international museums. Ivy has held executive positions ranging from head of product design and development to CMO and presidencies of several companies, including Calvin Klein, Swatch, Coach, Mattel, Bausch & Lomb, and Gap. Ninth on Fast Company's list of the 100 Most Creative People in Business 2019, Ivy believes the intersection of arts and science is where the most engaging and creative ideas are found. SHOW INTRO: Welcome to season five of the next level experience design podcast. It's kind of amazing when I think of it… now five seasons… wow.This season will be no different than the previous ones where we continue to have great discussions with visionary leaders from various industries and professions. These dynamic dialogues based on our acronym DATA - design, architecture, technology, and the arts crosses over disciplines but maintains a common thread of people who are passionate about the world we live in and human's influence on it, the ways we craft the built environment to maximize human experience, increasing our understanding of human behavior and searching for the New Possible.As we jump into this new season thanks go to VMSD magazine. You will find the archive of the NXTLVL experience design podcast on VMSD.com. VMSD is the publisher of VMSD magazine and brings us, in the brand experience world, the International Retail Design Conference. The IRDC is one of the best retail design conferences that there is bringing together the world of retailers, brands and experience placemakers every year for two days of engaging conversations and pushing the discourse forward on what makes retailing relevant.Thanks also goes to Shop Association the only global retail trade association dedicated to elevating the in-store experience. SHOP Association represents companies and affiliates from 25 countries and brings value to their members through research, networking, education, events and awards. Check then out on SHOPAssociation.orgOK, let's dig in... With our first interview of the season with two remarkable women Susan Magsamen and Ivy Ross whose recent book “Your Brain on Art has garnered huge attention since its recent release. But first a few thoughts on art and making...****************When I was about 9 years old and my mom had me in an after school art program at a local painting studio near my childhood home. Thursdays, as it would turn out, became the single time of the week where the outside world disappeared and I entered into a place of pure creativity and innovation which many years later I would discover was called “flow.”Even to this day Thursdays seemed to hold a special body memory for me of calm and an internal sense of both peace and joy. Thursdays somehow carry a different energy from me that I think was implanted in my body all those years ago where my creative passion was fully expressed.For years I would paint on Thursdays and that turned into a passion that became a profession as an architect. I wasn't great at math or physics but I was pretty confident about my skills in art and I knew that there was something specific about the feeling that I had in going to this small art studio that was because of the things I was doing as well as the place that I was doing it in. So studying architecture was always grounded in this idea for me of creating places that moved people emotionally. It didn't matter to me too much whether you loved it or hated it, although I would have preferred you loved it. But my goal was always to connect to people on an emotional level to find the right combination of materials and finishes space volumes and textures and all those other things that we have in our architects toolbox and how we moved through and experience space from a mind – body emotional perspective.I think early on I developed an aesthetic mindset. I seemed to have a high level of curiosity, a love of play and open-ended exploration, a keen sensory awareness and a drive to engage in activities as a maker or beholder. Through my architecture studies at McGill University I discovered principles of experience rooted in ritual and that there was a very different physical and emotional feeling connected to participating in ritual versus simply watching them. I was always very interested in how people participated in space. How they participated in the making of their experiences because I always believed that in making we brought something unique to the world that humans were capable of doing better than any other creatures on the planet. I developed a keen interest in ontological design - basically put - that the things we make return the favor by in part making us who we are. Our neurobiology reacts to the environment around us and so our mind body state is directly influenced by what we experience in the built environment. Our brains are in a feedback loop of making and being made by experience.The Irish poet John O'Donoghue once said “art is the essence of awareness” and I find that particularly relevant to how we experience the places that we build and how we interact with them. What I learned as a young artist on Thursday afternoons was that somehow in the making of things I became acutely aware of my mind body state as well as my surroundings.As I started to create and design retail places it seemed that everywhere I walked the world around me became more relevant I was tuning in to everything that I could see and hear. When in the middle of trying to solve a design challenge, I seemed to tune into things that might not have otherwise been apparent to me.What I found interesting was that this attunement to the environment around me also grew a connection between my sensory experiences and my appreciation of art. As I engaged more fully in the environment around me and the various kinds of arts I also learned more about myself. During the recent pandemic I turned to painting to help navigate the uncertainty and ambiguity of a global crisis that had left everything that I had believed to be true and a path that I had created for myself professionally in flux. Art it seemed became the grounding mechanism that calmed my nervous system that brought joy amidst uncertainty.Over the past few decades as a creative architect I've become acutely aware that the environment around us has a profound effect on our mind body state, our sense of well-being, our feelings of joy, community, connection, belonging, relevance. Being exposed to the arts provided context and meaning, a way for me to understand where I stood in the grand scheme of things. And art also gave me a sense of agency of being able to have a sense of control and to bring things into the world that had never been there before.And so, because of all of these understandings I have a deep appreciation for the book recently published by Susan Magsamen and Ivy Ross called “Your Brain on Art: How the Arts Transform Us.”This book is wildly successful because I believe it is a writing whose time has come. It brings forward the ideas that the arts are fundamental to who we are as people and that long before we had written language we danced around fires sang songs, made drawings on walls and shared the meaning of our lives with each other by being in community, in relationships, participating in rituals and making. And so, it's not surprising that the arts in all of its forms visual, literary, dance, sculpture and others are part of who we are as individuals and as members of a broader human whole.When I bought this book I thought that it would help me understand the neuroscience of what was happening in my brain as I stood in front of a painting. But it did more than that. It helped to unpack why I was led to feel certain ways about my experience of art in general including paintings, dance, musical theater, poetry, a good movie and a great book.It was chock full of examples and great research on how the arts are used in healing practices and health care industry to augment patient recovery. It looked at how the arts are being used in education, though not nearly enough, to enhance learning.Your brain on Art also brought me greater understanding about making music and how memories are tied to our experiences of hearing music. That's why it's likely you can clearly remember tunes from your childhood and tag them to early childhood experiences. Or why your playlists from your high school years probably are still able to be recalled with ease. And why I can remember the high school dance and my girlfriend at the time and the song Lucky Man by Emerson Lake and Palmer and that kiss.The book dives into understanding arts and the neurodivergent brain and play and how these are critical to our development.And if all of that wasn't quite enough it digs into the idea of how the arts support flourishing and asks the question - What constitutes a good life? I did not know that there is a burgeoning subfield of neuroscience and psychology now dedicated to identifying and understanding the neural mechanisms that contribute to a state of flourishing. And Your Brain on Art brings to light some of the neuroscience related to creativity, awe and wonder.Your Brain on Art is a collaborative effort between two remarkable women who together combine neuroscience and creative vision into a must-read book.Susan Magsamen has over 35 years of experience in developing effective learning programs rooted in the science of learning and is an active member of the brain sciences research, arts, education and social impact communities. She currently serves as Executive Director of the International Arts and Mind Lab, Center for Applied Neuroaesthetics at the Brain Science Institute at Johns Hopkins University where she is also a faculty member. She is also the senior advisor to the Science of Learning Institute at Johns Hopkins University. She works with both the public and private sectors using arts and culture evidence based approaches in areas including health, child development, workforce innovation, rehabilitation and social equity.Ivy Ross is the Vice President of Design for the Hardware organization at Google. Over the past six years, she and her team have launched 50+ products winning over 240 global design awards. This collection of hardware established a new Google design aesthetic that is tactile, colorful, and bold. She is a winner of a National Endowment for the Arts grant, and her innovative metal work in jewelry is in the permanent collections of 12 international museums. Ivy has held executive positions ranging from head of product design and development to CMO and presidencies of several companies, including Calvin Klein, Swatch, Coach, Mattel, Bausch & Lomb, and Gap. Ninth on Fast Company's list of the 100 Most Creative People in Business 2019, Ivy believes the intersection of arts and science is where the most engaging and creative ideas are found. ABOUT DAVID KEPRON:LinkedIn Profile: linkedin.com/in/david-kepron-9a1582bWebsites: https://www.davidkepron.com (personal website)vmsd.com/taxonomy/term/8645 (Blog)Email: david.kepron@NXTLVLexperiencedesign.comTwitter: DavidKepronPersonal Instagram: https://www.instagram.com/davidkepron/NXTLVL Instagram: https://www.instagram.com/nxtlvl_experience_design/Bio:David Kepron is a multifaceted creative professional with a deep curiosity to understand ‘why', ‘what's now' and ‘what's next'. He brings together his background as an architect, artist, educator, author, podcast host and builder to the making of meaningful and empathically-focused, community-centric customer connections at brand experience places around the globe. David is a former VP - Global Design Strategies at Marriott International. While at Marriott, his focus was on the creation of compelling customer experiences within Marriott's “Premium Distinctive” segment which included: Westin, Renaissance, Le Meridien, Autograph Collection, Tribute Portfolio, Design Hotels and Gaylord hotels. In 2020 Kepron founded NXTLVL Experience Design, a strategy and design consultancy, where he combines his multidisciplinary approach to the creation of relevant brand engagements with his passion for social and cultural anthropology, neuroscience and emerging digital technologies. As a frequently requested international speaker at corporate events and international conferences focusing on CX, digital transformation, retail, hospitality, emerging technology, David shares his expertise on subjects ranging from consumer behaviors and trends, brain science and buying behavior, store design and visual merchandising, hotel design and strategy as well as creativity and innovation. In his talks, David shares visionary ideas on how brand strategy, brain science and emerging technologies are changing guest expectations about relationships they want to have with brands and how companies can remain relevant in a digitally enabled marketplace. David currently shares his experience and insight on various industry boards including: VMSD magazine's Editorial Advisory Board, the Interactive Customer Experience Association, Sign Research Foundation's Program Committee as well as the Center For Retail Transformation at George Mason University.He has held teaching positions at New York's Fashion Institute of Technology (F.I.T.), the Department of Architecture & Interior Design of Drexel University in Philadelphia, the Laboratory Institute of Merchandising (L.I.M.) in New York, the International Academy of Merchandising and Design in Montreal and he served as the Director of the Visual Merchandising Department at LaSalle International Fashion School (L.I.F.S.) in Singapore. In 2014 Kepron published his first book titled: “Retail (r)Evolution: Why Creating Right-Brain Stores Will Shape the Future of Shopping in a Digitally Driven World” and he is currently working on his second book to be published soon. David also writes a popular blog called “Brain Food” which is published monthly on vmsd.com. ************************************************************************************************************************************The next level experience design podcast is presented by VMSD magazine and Smartwork Media. It is hosted and executive produced by David Kepron. Our original music and audio production by Kano Sound. The content of this podcast is copywrite to David Kepron and NXTLVL Experience Design. Any publication or rebroadcast of the content is prohibited without the expressed written consent of David Kepron and NXTLVL Experience Design.Make sure to tune in for more NXTLVL “Dialogues on DATA: Design Architecture Technology and the Arts” wherever you find your favorite podcasts and make sure to visit vmsd.com and look for the tab for the NXTLVL Experience Design podcast there too.
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, September 13, 2023. Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast. Procept BioRobotics this week won an FDA investigational device exemption (IDE) for its Aquablation prostate cancer therapy. Fast Five hosts Danielle Kirsh and Sean Whooley explain what the therapy is and what the company's plans are for the IDE. The FDA has approved LimFlow's chronic limb-threatening ischemia (CLTI) treatment device. The approval enables the treatment to help those with CLTI with no other suitable endovascular or surgical treatment options available. Whooley dives into the device design in this episode. Shockwave Medical is appointing a former Abbott Vascular executive as its chief medical officer. Find out who's taking on this role and what their career history is. Bausch+Lomb launched a sizeable offering of senior secured notes worth $1.4 billion. Whooley explains the purpose behind the offering and provides more details into the company's latest acquisition. Orthofix this week fired its CEO and two other executives with cause. After the announcement, analysts downgraded the company. The Fast Five hosts talk about the terminations, why the board made this decision and what analysts were thinking.
Bausch + Lomb's Director for Consumer Marketing, Tatyana Jones, is no stranger to the complexities of CPG marketing in today's noisy landscape. That's why her shiny new object is simplicity - in particular, doing the common, uncommonly well. Find out how to pare down your marketing strategy and boost creative effectiveness in the latest episode of the Shiny New Object. Tatyana also shares her three-pillar approach to simple marketing and the worst marketing advice she's ever heard.
Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.Activity OverviewThis PER® Spectives™ podcast features a discussion among 3 optometrists on challenges and unmet needs associated with traditional treatments for meibomian gland dysfunction (MGD)-related dry eye disease (DED) — and opportunities for MGD treatment that may come with new and emerging topical therapies. In addition, the panel discusses myths and misconceptions that may affect outcomes in patients with MGD-DED. This program is designed to help clinicians better appreciate the impact ofMGD-DED on patients and optimize the growing toolkit of available therapies.Accreditation/Credit DesignationPhysicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Bausch + Lomb.Target Audience This educational activity will be targeted to practitioners who are involved in treating patients with MGD, such as Optometrists, Ophthalmologists, NPs, PAs, and nurses.Learning ObjectivesUpon successful completion of this activity, you should be better prepared to: • Analyze key trial data and real-world evidence surrounding current treatments for MGD-associatedDED• Evaluate key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DEDFaculty:Mile Brujic, OD, FAAOPartnerPremier Vision GroupBowling Green, OHDisclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, WalmanOptical, ZeaVisionDavid Kading, OD, FAAO, FCLSADisclosuresWalter Whitley, OD, MBA, FAAODirector of Professional Relations and EducationRegional Medical Director - Mid-AtlanticEyeCare Partners, LLCDisclosures: Consultant: Alcon, Allergan, Bausch + Lomb, Bruder, I-MED Pharma USA, KalaPharmaceuticals, Novartis, Oyster Point Pharma, Regener-Eyes, Santen Pharmaceutical, ScienceBasedHealth, Sun Pharma, Tarsus Pharmaceuticals, Théa Pharma; Speakers' Bureau: Alcon, Allergan, Bausch +Lomb, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, Santen Pharmaceutical, ScienceBasedHealth, Sun Pharma.The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs.Learners are advised to consult prescribing information for any products discussed. Theinformation provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support
Two recent drug approvals changed the game for ocular surface disease: Xdemvy (lotilaner ophthalmic solution) 0.25 percent (Tarsus Pharmaceuticals) for Demodex blepharitis, and Miebo (perfluorohexyloctane ophthalmic solution) from Bausch + Lomb and Novaliq for evaporative dry eye disease. On today's podcast, two ocular surface disease experts talk about these and other developments related to dry eye.Our guests:Laura Periman, MD, aka “the dry eye master” and founder of Periman Eye InstituteLisa Nijm, MD, JD, a corneal, cataract, and Lasik specialist at Warrenville Eyecare and Lasik in Warrenville, IllinoisDr. Periman was an investigator in the Xdemvy clinical trials, and Dr. Nijm was involved in an extended observational study.“Before Xdemvy, patients' options were limited,” Dr. Nijm told host Carey Powers. “When treated with Xdemvy, at one year, about 60 percent of patients still had clearance of Demodex.”Periman noted that during clinical trials, within a week or two she noticed “impressive improvements” in redness, reduction of collarette, and mite load in patients treated with Xdemvy. She also said the drug was “extremely well tolerated.”Miebo, a product designed to prevent excessive tear evaporation in patients with dry eye, is also expected to bring relief to a wide number of people. Dr. Periman sees Miebo as a “rapid go-to” for patients with an evaporative component, as it will potentially allow the ocular surface to protect the cornea as it's supposed to.These two products alone will help make ocular surface diseases easier to manage; however, other exciting innovations emerging later this year could liven up the playing field.Listen to the podcast today to discover:Drs. Periman and Nijm's insights into the Xdemvy clinical trias and why they're not surprised the drug received early FDA approval.How to identify Demodex in the clinic: a quick tip from Dr. Periman.Why patient education around lid hygiene remains important even with use of Xdemvy.How to best use the latest dry eye treatments to treat ocular surface disease.What makes Miebo a unique and widely applicable product.Innovations on the horizon in dry eye disease, from pharmaceuticals to neurostimulators.How the aesthetic components of dry eye disease factor into clinical care.[Listen Now]ResourcesLisa Nijm, MD, JD: warrenvilleeyecare.comLaura Periman, MD: dryeyemaster.com/about-laura-perimanCarey Powers: ois.net/carey-powers
Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.Activity OverviewThis PER® Spectives™ podcast features a discussion among 3 optometrists on concerns related to the use of preserved eye lubricants for patients with dry dye disease. In addition, the panel discusses developments in components within these products to support the ocular surface, including trehalose and hyaluronic acid. This program is designed to help clinicians better match specific eye lubrication products to individual patient needs, thereby improving the chances of superior outcomes.Accreditation/Credit DesignationPhysicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Thea Pharmaceuticals, Inc.Target Audience This educational activity will be targeted to clinicians who are involved in treating patients with dry eye disease such as optometrists, ophthalmologists, NPs, PAs, and nurses.Learning ObjectivesUpon successful completion of this activity, you should be better prepared to: • Recognize the potential deleterious impact preservatives have on the ocular surface• Summarize novel formulations for the management of DEDFaculty:Mile Brujic, OD, FAAOPartnerPremier Vision GroupBowling Green, OHDisclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, WalmanOptical, ZeaVisionDavid Kading, OD, FAAO, FCLSACEO/OwnerSpecialty EyeKirkland, WA / Bellevue,WADisclosures:Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, CooperVision, EyeVance, Eye Promise Euclid, Horizon Lumenis, Oculus,Orasis, Oculaphire, Medmont, Novartis, Sun Pharma, TearScience, Thea, Trukara, Valley Contax, Visus Theraputics, Zeiss, andZeaVision.DisclosuresSelina R. McGee, OD, FAAOCEO/OwnerBeSpoke VisionPresidentIntrepid Eye SocietyOklahoma Board of Examiners in OptometryEdmond, OKDisclosures: Consultant: Horizon Therapeutics.The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs.Learners are advised to consult prescribing information for any products discussed. Theinformation provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial supportfor this activity.
Yari Mitchell spent nearly 13 years with AcuFocus, an ophthalmic device company, before overseeing its acquisition by Bausch + Lomb. As head of Y Factor Consulting, she now helps innovators move their product from the lab to a funded company.Greg Kunst, President and CEO of Aurion Biotech, a cell therapy company, led the start-up to a $120 million raise in 2022.Both Mitchell and Kunst sat down with host Carey Powers to discuss two topics they're more than familiar with: raising capital and navigating M&As.When you're working to raise funding, a gift for storytelling will take you far, they said. That story must show how your product will take market share or otherwise deliver value. The story must be unique enough to spark interest, but not so unique that it scares off investors.“You need to have a clear unmet need and you have to be different,” said Kunst.Start-up founders must also consider reimbursement paths as early in the process as feasible.Mitchell and Kunst also advised listeners on how to stand out when you have a limited budget. Hint: an organized pitch deck trumps a flashy but disjointed presentation.Navigating topics ranging from product differentiation to pitching complex scientific ideas to running out of money, both Mitchell and Kunst came back to a quote commonly attributed to Zig Ziglar:“It's never as good or as bad as you think it is.”Listen to the podcast today to discover:Start-ups solve scientific problems in many ways. Does that approach make it easier or more difficult to sell to investors?The areas that are most critical to invest when you want to differentiate yourself from the competition—without blowing the budget.The importance of physician voices when building a brand.How Mitchell and Kunst overcame some of the biggest obstacles in their paths.Advice to stay financially and emotionally stable while building a start-up.The importance of disconnecting.Their thoughts on ChatGPT and its impact on patient education.[Listen Now]ResourcesYari Mitchell: linkedin.com/in/yarimitchellGreg Kunst: linkedin.com/in/greg-kunst-16647a1Y Factor Consulting: linkedin.com/company/y-factor-consulting-incCarey Powers: https://ois.net/carey-powers
Get an overview of the recently FDA-approved perfluorohexyloctane ophthalmic solution (Miebo, Bausch + Lomb) from Jackie Garlich, OD, FAAO, and Leslie O'Dell, OD, FAAO. Drs. O'Dell and Garlich discuss the drop's mechanism of action, dosing regimen, clinical trial findings, side effect profile, and more.
Welcome, 7 Hatters! Brace yourselves for an episode teeming with creative insights as we engage in conversation with John Livesay... and decode the mysteries of a sales and storytelling guru's life, plunging deep into hats 3 and 4, the servant and entrepreneur.John is a force to reckon with in the sales, marketing, and storytelling world, boasting a diverse career that crosses various industries and roles. Currently, he's captivating audiences globally as the acclaimed "Pitch Whisperer," inspiring confidence and winning business pitches.Many sales teams in tech and healthcare, including those at Olympus Medical and Bausch+Lomb, turned to John when they were tired of being seen as just another vendor stuck in second place in business pitches. They were tired of pushing out forgettable facts, being on a self-esteem roller coaster, and burning out. John knows this pain all too well, having experienced it himself.Having secured the Salesperson of the Year title at Conde Nast and authored four books on the power of storytelling as a sales tool, John's keynote talks are an ideal fusion of inspiration and actionable takeaways. Apart from his impactful keynote speeches and coaching sessions, John is also an author. His latest book, "The Sale is in the Tale," brilliantly blends storytelling with sales, demonstrating the art of storytelling in business.So, if you're ready to swap forgettable facts for compelling stories, win pitches confidently, and evolve into the entrepreneur who charms with narratives and triumphs in sales... let's roll out the 7 Hats welcome mat for John Livesay...-------------------------Visit https://www.the7hats.com/ for more information and more shows.John on LinkedIn: https://www.linkedin.com/in/jlivesay/John's Website: https://johnlivesay.com/My Bio & Links: https://sleek.bio/yuvalselikSUBSCRIBE AND REVIEW...Want to be the first to know when new episodes are released? Please subscribe and leave a review!Subscribes and podcasts reviews are pretty darn important to iTunes, and the more reviews we receive, the more likely we'll be able to get The 7 Hats message in front of more people (It's all about the iTunes algorithms)I'd be extremely grateful if you left a review letting me know your favorite part of the show or episode :)
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTS with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space. · Welcome to the Eyeluminaries podcast :01 · Review of episode 16 with Stephen McLeod, MD :28 · Preview of episode 17, live at Octane OTS 1:00 · Introduce Mark Leahey, president & CEO for the Medical Device Manufacturers Association 1:23 · Challenges in medical device 2:19 · Is it possible for the government to reduce regulation of medical devices while still protecting patients? 4:32 · What is MDMA doing for sustainability? 6:50 · What is one issue that device manufacturers need to implement? 9:04 · Introduce Brent Saunders, Chairman and CEO of Bausch + Lomb 12:23 · What's different about Bausch + Lomb today that wasn't around when you first worked for the company? 13:27 · Tell us about other products at Bausch + Lomb. 19:22 · Introducing Yari Mitchell, the president of Y Factor Consulting, Inc. 23:31 · What have been the most important changes in the ophthalmic industry over the past couple of years? 24:58 · What advice would you give to an early-career person? 26:15 · Favorite memories of Jim Mazzo 29:14 · Introducing Robert Dempsey, CEO and President of AsclepiX Therapeutics 32:10 · What was it like to leap from medical sciences to a leadership position? 33:22 · Managing a pipeline that includes both retinal and cornea treatments 35:05 · How do you establish yourself as a competitor in age-related macular degeneration research in a mature and crowded market with limited resources? 36:10 · Creating a retinal treatment delivered via the suprachoroidal route 37:28 · The Holland Foundation For Sight Restoration seeking to spread access to eye care for patients and the importance of giving back 38:27 · Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:00 · Thanks for listening 44:19 Robert Dempsey is the CEO and president of AsclepiX Therapeutics. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO of the Medical Device Manufacturers Association. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Yari Mitchell is the president of Y Factor Consulting, Inc. Brent Saunders is the chairman and CEO of Bausch + Lomb. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Dempsey is the president and CEO of AsclepiX Therapeutics. Hovanesian consults widely in the ophthalmic field. Leahey is the president & CEO for the Medical Device Manufacturers Association. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Mitchell is the chief business development officer at AcuFocus and the president of Y Factor Consulting, Inc. Saunders is the chairman and CEO of Bausch + Lomb.
The averages fell after the Fed announced it would raise interest rates by 0.25% and Jim Cramer is helping investors navigate a market impacted by the FOMC's policy change. First, Cramer's biting into Brinker International's most recent quarter with CEO Kevin Hochman. Then, should investors keep an eye on Bausch + Lomb? Cramer's talking to CEO Brent Saunders. Plus, Cramer's exclusive with Wingstop CEO Michael Skipworth. Mad Money Disclaimer
Blake Williamson, MD, MPH, and Gary Wörtz, MD, continue this season's theme of how to grow a business and welcome Brent Saunders, chairman and CEO of Bausch + Lomb, to discuss his experiences in ophthalmology. Mr. Saunders touches on how he defines business success, emphasizing the value of having a great mentor and encouraging young ophthalmologists not to shy away from taking risks.
If ophthalmology clinical trials were burgers, mitomycin would be the mustard at the table of every U.S. restaurant with a burger on the menu.*Using this analogy, Mitsol, developed and manufactured by Mobius Therapeutics, is the only FDA-approved mitomycin-c “mustard” formulation with an ophthalmic indication.In reality, the mitomycin story in ophthalmology is more complicated than that, says Ed Timm, Founder, Chairman, and CEO of Mobius Therapeutics.Mitomycin-c is used by ophthalmologists to prevent scarring during surgery. Before the FDA approved Mitosol, surgeons would have to obtain a formulation of the antimetabolite from a compounding pharmacy. Because of its instability, the effectiveness of off-label use could vary.All that changed with the arrival of Mitosol, which is a standardized product that requires no refrigeration, no light-shielding, and has a 24-month shelf life.Unfortunately, ophthalmologists still have to develop off-label formulations of other products for use during surgery, which leads to unpredictable outcomes.Mobius is doing its part to change that.With podcast host Rob Rothman, MD, Timm discusses the benefits of using an assuredly sterile, assuredly potent product and Mobius's plans to expand Mitosol's use beyond glaucoma surgery, keratectomy and pterygium.*Burger-mustard analogy courtesy of Ed TimmListen to the podcast today to discover:The Mobius strategy to expand into other indications and specialties.Timm's take on recent recalls of contaminated eye drops and what it means for development and manufacturing moving forward.Mobius's plans for growth over the next few years, including potential strategic partnerships.Timm's professional background, which took him from American Hospital Supply to building Synergetics (later sold to Bausch + Lomb) to Mobius Therapeutics.What Dr. Rothman sees as a recurring theme in ophthalmology and how it creates better leaders and investors.[Press Play]
As Vice President and General Manager of U.S. Surgical for Bausch + Lomb, Anthony Wallace is involved in virtually all things surgical. His day-to-day includes strategy, portfolio planning, R&D alignment, acquisitions, pricing and contracting, sales and marketing, and supply chain.On top of all that, he's one of the key executives leading Bausch + Lomb's five-year charge: double the number of patients reached from 2 million to 4 million.During a candid discussion with podcast host and retina surgeon Firas Rahhal, MD, Wallace discusses how current healthcare policy will affect surgical device and drug development, pricing, and patient outcomes.He also shares stories from his tenure at Novartis, including the dark time when the company called off three Beovu clinical trials due to cases of occlusive vasculitis. “It was the fastest I've seen any company move and it was in the name of patient safety,” he said.Listen to the podcast today to discover:The feedback Bausch + Lomb has received on Stellaris Elite for both cataract and retina procedures and how the company plans to improve on the device.Details on the Bi-Blade vitrectomy cutter and the significant upgrade Bausch + Lomb is currently testing.How Wallace identifies gap areas in surgical tools to build out the Bausch + Lomb pipeline.More details on what Wallace's job entails as VP and GM of U.S. Surgical for Bausch.Lessons learned from nearly a decade at Novartis.An update on Bausch + Lomb's Synergetics acquisition from 2016 and the state of the relationship after seven years together.What's makes the retina space unique compared to other therapeutic areas.How the Inflation Reduction Act impact drug and device development, short and long term.What's ahead for ophthalmology innovation in the next three to five years.[Press Play]
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology. Welcome to the Eyeluminaries podcast :00 OTF Meeting 01:41 Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04 Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42 The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21 Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24 Best of the year award – Pegcetacoplan 6:49 Near miss award – Beovu (brolucizumab) 8:08 Awful award – Byooviz (ranibizumab-nuna) 8:45 Guest welcome 9:40 Richard L. Lindstrom, MD, introduction 10:31 FDA grants fast track designation for retinitis pigmentosa treatment 10:36 EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14 Amazon launches discount prescription drug service 17:46 Interview with Lindstrom 21:42 What is the biggest innovation in ophthalmology in your career? 22:40 What is coming in the next 10 years? 25:24 What is out there that will get in the way of innovation? 26:54 What advice would you give to residents? 28:35 What advice would you give to entrepreneurs? 30:16 What story can you share about one historical figure in ophthalmology? 31:59 Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14 Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29 Thanks for listening 36:53 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.
CooperVision's Global Head of Myopia Management Strategy, Rajeev Garg, made a bold move over a decade ago. After a fruitful career in R&D for Abbott and Merck, he got his MBA and transitioned to the commercial side. It worked out well. He led global teams for Johnson & Johnson and Bausch + Lomb before joining one of the industry's leading contact lens makers. With ophthalmologist and venture capitalist Ehsan Sadri, MD, Rajeev shares CooperVision's path forward for myopia innovation. CooperVision's MySight one-day contact lenses are the only FDA-approved contacts designed to slow the progression of myopia in children. CooperVision wants to build on that success by ramping up physician training and education as well as raising consumer awareness on the importance of slowing the progression of myopia. It's taking the lead through joint ventures, acquisitions, and other partnerships. CooperVision also encourages physicians to take the Myopia Management Pledge. Are you ready to make myopia management part of your practice? Listen to the podcast today to discover: · How Rajeev's experience in eye care has differed from other therapeutic areas. · Rajeev's career milestones at Bausch + Lomb, Johnson & Johnson, and CooperVision, and how innovation ties them together. · Rajeev's thoughts on how to address the myopia epidemic in Asia. · Details on CooperVision's multimodal treatment strategy. · Where Rajeev sees CooperVision evolving over the next few years. · His advice for emerging leaders on how to move through career obstacles and transitions. Hit “Play” to Listen.
Today's show is a really unique show in many ways. My guest Robert Grant, and I go into levels of water that have never been spoken about before in this podcast and maybe nowhere else. And it's a really fun conversation and you're going to see, hopefully the world from a new perspective and get some more insight from this very brilliant man and the way that he perceives the world and water. And a little bonus is relationships. This is a very high level human. Not only has he lived in nine different countries, Robert Grant's career and life have spanned a very broad spectrum of interests and educational disciplines. So professionally, he played a leading role in the global health care industry. Formerly the CEO of Bausch + Lomb and Allergan, and he covered diverse areas such as pharmaceutical, medical, device technology and as well as international health care systems. He's done TEDx talks, but what he's really known for now is his mathematics and geometry. Most recently, during the past decade, Robert has turned his attention and acumen toward number theory, mathematical physics, geometry, cryptography and blockchain cryptocurrencies. So he's a strong advocate of data sovereignty for the original producers of digital assets. So Robert and I talk water, we talk philosophical things, we talk relationships. He get real and we get deep. Please share this episode with somebody that you love. Enjoy. Find Robert on: Instagram - @robertedwardgrant YouTube - @Robert_Edward_Grant Website - robertedwardgrant.com For my favorite products, Check out: Sanctuarysd.com Timestamps: 4:56 - Who is Robert Edward Grant 12:43 - How did Robert get into Number theory, Mathematical Physics, Geometry
© 2020-2025 Ivy Podcast Discovery LLC
